CMBA
ECYT

C.M. Bidwell & Associates’s Endocyte, Inc. Common Stock ECYT Stock Holding History

C.M. Bidwell & Associates’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-22,250
Closed -$139K – 272
2015
Q1 		$139K Sell
22,250
-300
-1% -$1.73K 0.03% 183
2014
Q4 		$142K Buy
+22,550
New +$137K 0.03% 179

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

C.M. Bidwell & Associates's ECYT Position: Q2 2015 in Review

C.M. Bidwell & Associates sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2015, closing a stake of 22,250 shares — an estimated $139K sold.

C.M. Bidwell & Associates first reported a position in ECYT in Q4 2014 and held it in 2 quarters. The position peaked at $142K in Q4 2014. 98 funds tracked by Wall St. Rank hold ECYT as of Q2 2015.

  • C.M. Bidwell & Associates reported no remaining Endocyte, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 22,250 Endocyte, Inc. Common Stock shares in Q2 2015, an estimated $139K.
  • C.M. Bidwell & Associates first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Endocyte, Inc. Common Stock position peaked at $142K in Q4 2014.
  • 98 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2015.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2015, filed 21 Aug 2015.